{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:36:23Z","timestamp":1773740183956,"version":"3.50.1"},"reference-count":30,"publisher":"Informa Healthcare","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2007,4,1]]},"DOI":"10.1185\/030079907x178694","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T23:37:34Z","timestamp":1172101054000},"page":"683-689","source":"Crossref","is-referenced-by-count":21,"title":["Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure"],"prefix":"10.1185","volume":"23","author":[{"given":"Enyr S.","family":"Arcieri","sequence":"first","affiliation":[{"name":"Glaucoma Service, Department of Ophthalmology, University of Campinas (UNICAMP), Campinas, S\u00e3o Paulo, Brazil"},{"name":"Glaucoma Service, Department of Ophthalmology, Federal University of Uberl\u00e2ndia (UFU), Uberl\u00e2ndia, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael S.","family":"Arcieri","sequence":"additional","affiliation":[{"name":"Glaucoma Service, Department of Ophthalmology, Federal University of Uberl\u00e2ndia (UFU), Uberl\u00e2ndia, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C. A.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Santa Casa de Campo Grande, Campo Grande, Mato Grosso do Sul, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo G. V.","family":"Andreo","sequence":"additional","affiliation":[{"name":"Glaucoma Service, Department of Ophthalmology, Federal University of Uberl\u00e2ndia (UFU), Uberl\u00e2ndia, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion\u00e1 G. A.","family":"Finotti","sequence":"additional","affiliation":[{"name":"Glaucoma Service, Department of Ophthalmology, Federal University of Uberl\u00e2ndia (UFU), Uberl\u00e2ndia, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanderley F.","family":"S\u00e1 Filho","sequence":"additional","affiliation":[{"name":"Glaucoma Service, Department of Ophthalmology, Federal University of Uberl\u00e2ndia (UFU), Uberl\u00e2ndia, Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2007,2,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810293391808"},{"key":"CIT0002","doi-asserted-by":"crossref","unstructured":"Stewart WC, Sharpe ED, Harbin TS Jr, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000;129: 723\u20137","DOI":"10.1016\/S0002-9394(00)00381-0"},{"key":"CIT0003","first-page":"375","volume":"29","author":"Francis BA","year":"2004","journal-title":"5% timolol \u2013 a randomized controlled trial and a replacement study. J Clin Pharm Ther"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.11.1249"},{"key":"CIT0005","first-page":"615","volume":"110","author":"Sall KN","year":"2003","journal-title":"Dorzolamide\/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology"},{"key":"CIT0006","first-page":"61","volume":"274","author":"Zeyen T","year":"1999","journal-title":"Bull Sot Beige Ophtalmol"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.1.12"},{"key":"CIT0008","first-page":"775","volume":"14","author":"Kass MA","year":"1982","journal-title":"Part I. Patient administration of eyedrops: interview. Ann Ophthalmol"},{"key":"CIT0009","first-page":"889","volume":"14","author":"Kass MA","year":"1982","journal-title":"Part II. Ann Ophthalmol"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1159\/000059624"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1007\/BF02853166"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)91046-6"},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Strahlman E, Tipping R, Vogel R, International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995;113: 1009\u201316","DOI":"10.1001\/archopht.1995.01100080061030"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090100051026"},{"key":"CIT0015","first-page":"454","volume":"20","author":"Rusk C","year":"1998","journal-title":"Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin Ther"},{"key":"CIT0016","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue EP, UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br J Ophthalmol 2000;84: 579\u201382","DOI":"10.1136\/bjo.84.6.579"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1089\/108076803322660431"},{"key":"CIT0018","first-page":"953","volume":"88","author":"Sharpe ED","year":"2004","journal-title":"15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200204000-00003"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(Suppl):S27\u201337","DOI":"10.1016\/S0039-6257(96)82029-7"},{"key":"CIT0021","first-page":"1969","volume":"23","author":"DuBiner HB","year":"2001","journal-title":"Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multi-center, randomized, double-masked, parallel-group trial. Clin Ther"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(Suppl):S19\u201326","DOI":"10.1016\/S0039-6257(96)82028-5"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100010079024"},{"key":"CIT0024","first-page":"168","volume":"13","author":"Whitson JT","year":"2004","journal-title":"2% in patients with glaucoma or ocular hypertension. J Glaucoma"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200012000-00007"},{"key":"CIT0026","first-page":"163","volume":"79","author":"Carrasco Font C","year":"2004","journal-title":"2% and dorzolamide 2% as adjunctive therapy to beta-blockers [in Spanish]. Arch Soc Esp Oftalmol"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1999;106(Suppl):1\u20139","DOI":"10.1016\/S0161-6420(99)90281-6"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2005.21.337"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"Go\u00f1i FJ. The Brimonidine\/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15: 581\u201390","DOI":"10.1177\/112067210501500508"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200404000-00012"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079907X178694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T04:11:08Z","timestamp":1598674268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079907X178694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,20]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4,1]]}},"alternative-id":["10.1185\/030079907X178694"],"URL":"https:\/\/doi.org\/10.1185\/030079907x178694","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,20]]}}}